Replies to post #148119 on Biotech Values

[DewDiligence]

Shacknai has continued to conduct MRX’s CC’s in the same exacting style as always, as though nothing whatsoever had changed. It must have been an act.

In any event, Shacknai has enough money for 100 lifetimes. MRX was one of the top success stories in specialty pharma during the past two decades.

[DewDiligence]

Two ambulance chasers already horning in on the VRX-MRX deal:

http://finance.yahoo.com/news/medicis-pharmaceutical-shareholder-alert-briscoe-155300120.html
http://finance.yahoo.com/news/law-firm-kirby-mcinerney-llp-153210365.html

MRX won’t be able to fetch a better price from someone else, IMO.